



(12) Translation of
European patent specification

(11) NO/EP 2870160 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 491/18 (2006.01)
A61K 31/4745 (2006.01)
A61K 31/4985 (2006.01)
A61K 31/4995 (2006.01)
A61K 31/506 (2006.01)
A61K 31/519 (2006.01)
A61K 38/21 (2006.01)
A61P 31/14 (2006.01)
C07K 5/08 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2017.02.13
(80)	Date of The European Patent Office Publication of the Granted Patent	2016.09.28
(86)	European Application Nr.	13739324.5
(86)	European Filing Date	2013.07.02
(87)	The European Application's Publication Date	2015.05.13
(30)	Priority	2012.07.03, US, 201261667806 P 2013.03.15, US, 201361798524 P
(84)	Designated Contracting States:	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
	Designated Extension States:	BA ME
(73)	Proprietor	Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, US-USA
(72)	Inventor	BJORNSON, Kyla, c/o Gilead Sciences Inc.333 Lakeside Drive, Foster City, CA 94404, US-USA CANALES, Eda, c/o Gilead Sciences Inc.333 Lakeside Drive, Foster City, CA 94404, US-USA COTTELL, Jeromy, J., c/o Gilead Sciences Inc.333 Lakeside Drive, Foster City, CA 94404, US-USA KARKI, Kapil, Kumar, c/o Gilead Sciences Inc.333 Lakeside Drive, Foster City, CA 94404, US-USA KATANA, Ashley, Anne, c/o Gilead Sciences Inc.333 Lakeside Drive, Foster City, CA 94404, US-USA KATO, Darryl, c/o Gilead Sciences Inc.333 Lakeside Drive, Foster City, CA 94404, US-USA KOBAYASHI, Tetsuya, c/o Gilead Sciences Inc.333 Lakeside Drive, Foster City, CA 94404, US-USA LINK, John, O., c/o Gilead Sciences Inc.333 Lakeside Drive, Foster City, CA 94404, US-USA MARTINEZ, Ruben, c/o Gilead Sciences Inc.333 Lakeside Drive, Foster City, CA 94404, US-USA PHILLIPS, Barton, W., c/o Gilead Sciences Inc.333 Lakeside Drive, Foster City, CA 94404, US-USA PYUN, Hyung-jung, c/o Gilead Sciences Inc.333 Lakeside Drive, Foster City, CA 94404, US-USA SANGI, Michael, c/o Gilead Sciences Inc.333 Lakeside Drive, Foster City, CA 94404, US-USA SCHRIER, Adam, James, c/o Gilead Sciences Inc.333 Lakeside Drive, Foster City, CA 94404, US-USA SIEGEL, Dustin, c/o Gilead Sciences Inc.333 Lakeside Drive, Foster City, CA

94404, US-USA
 TAYLOR, James, G., c/o Gilead Sciences Inc.333 Lakeside Drive, Foster City, CA
 94404, US-USA
 TRAN, Chinh, Viet, c/o Gilead Sciences Inc.333 Lakeside Drive, Foster City, CA
 94404, US-USA
 TREJO MARTIN, Teresa, Alejandra, c/o Gilead Sciences Inc.333 Lakeside Drive,
 Foster City, CA 94404, US-USA
 VIVIAN, Randall, W., c/o Gilead Sciences Inc.333 Lakeside Drive, Foster City, CA
 94404, US-USA
 YANG, Zheng-Yu, c/o Gilead Sciences Inc.333 Lakeside Drive, Foster City, CA
 94404, US-USA
 ZABLOCKI, Jeff, c/o Gilead Sciences Inc.333 Lakeside Drive, Foster City, CA
 94404, US-USA
 ZIPFEL, Sheila, c/o Gilead Sciences Inc.333 Lakeside Drive, Foster City, CA 94404,
 US-USA

(74) Agent or Attorney Tandbergs Patentkontor AS, Postboks 1570 Vika, 0118 OSLO, Norge

(54) Title **INHIBITORS OF HEPATITIS C VIRUS**


(56) References
 Cited: WO-A1-2007/016441
 SRIKANTH VENKATRAMAN ET AL: "Macrocyclic inhibitors of HCV NS3 protease", EXPERT
 OPINION ON THERAPEUTIC PATENTS, vol. 19, no. 9, 1 September 2009 (2009-09-01), pages
 1277-1303, XP055084885, ISSN: 1354-3776, DOI: 10.1517/13543770903044994
 CHEN SHU-HUI ET AL: "Discovery of small-molecule inhibitors of HCV NS3-4A protease as
 potential therapeutic agents against HCV infection", CURRENT MEDICINAL CHEMISTRY,
 BENTHAM SCIENCE PUBLISHERS, NL, vol. 12, no. 20, 1 September 2005 (2005-09-01),
 pages 2317-2342, XP009110972, ISSN: 0929-8673, DOI: 10.2174/0929867054864769
 RABOISSON P ET AL: "Structure-activity relationship study on a novel series of cyclopentane-
 containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the
 discovery of TMC435350", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON,
 GB, vol. 18, no. 17, 1 September 2008 (2008-09-01), pages 4853-4858, XP024100116, ISSN:
 0960-894X, DOI: 10.1016/J.BMCL.2008.07.088 [retrieved on 2008-07-24]

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav


1. En forbindelse med formel IVa:

5



eller et farmasøytisk akseptabelt salt derav.


10 **2.** En forbindelse ifølge krav 1, som er en forbindelse med formel IVb:




eller et farmasøytisk akseptabelt salt derav.

15

3. En forbindelse ifølge krav 1, som er en forbindelse med formel IVb:




4. En forbindelse med formel IVc:



5 eller et farmasøytisk akseptabelt salt derav.


5. En forbindelse ifølge krav 4, som er en forbindelse med formel IVd:



10


eller et farmasøytisk akseptabelt salt derav.

6. En forbindelse ifølge krav 4, som er en forbindelse med formel IVd:




15

7. En forbindelse med formel IVe :



5 eller et farmasøytisk akseptabelt salt derav.


8. En forbindelse ifølge krav 7, som er en forbindelse med formel IVf:



10


eller et farmasøytisk akseptabelt salt derav.

9. En forbindelse ifølge krav 7, som er en forbindelse med formel IVf:




15

10. En forbindelse med formel IVg:



5 eller et farmasøytisk akseptabelt salt derav.


11. En forbindelse ifølge krav 10, som er en forbindelse med formel IVh:



10

eller et farmasøytisk akseptabelt salt derav.

12. En forbindelse ifølge krav 10, som er en forbindelse med formel IVh:



15

13. En farmasøytisk sammensetning omfattende en forbindelse ifølge hvilket som helst av kravene 1-12, eller et farmasøytisk akseptabelt salt derav, og en farmasøytisk akseptabel eksipiens.

5 **14.** En forbindelse ifølge hvilket som helst av kravene 1 til 12, eller et farmasøytisk akseptabelt salt derav for anvendelse i medisinsk terapi.

15. Farmasøytisk sammensetning ifølge krav 13, for anvendelse ved behandling av hepatitt C virusinfeksjon.

10

16. En forbindelse ifølge hvilket som helst av kravene 1 til 12, eller et farmasøytisk akseptabelt salt derav, for anvendelse ved profylaktisk eller terapeutisk behandling av en hepatitt C virusinfeksjon.